# Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation

> **NCT01366612** · PHASE3 · TERMINATED · sponsor: **Hackensack Meridian Health** · enrollment: 53 (actual)

## Conditions studied

- Myeloid Malignancies
- Acute Myelogenous Leukemia
- Chronic Myelogenous Leukemia
- Myeloproliferative Disorders
- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose)
- **DRUG:** Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)

## Key facts

- **NCT ID:** NCT01366612
- **Lead sponsor:** Hackensack Meridian Health
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06-16
- **Primary completion:** 2020-08-17
- **Final completion:** 2020-08-18
- **Target enrollment:** 53 (ACTUAL)
- **Why stopped:** Lack of Accrual
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01366612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01366612, "Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01366612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*